Victim of the coronavirus and the flu



Possible coexistence of the influenza virus with the SARS-CoV-2 epidemic in the coming winter is a challenge for public health. Dimopoulos (Rector of EKPA) reviews the data from recent publications in the prestigious scientific review JAMA (TM Uyeki et al. Preparing for the 2020-2021 Influenza Season. JAMA. November 2, 2020. and TM Uyeki High-risk Groups for Influenza Complications. Prevention measures against SARS-CoV-2, such as universal mask use, restriction of social interactions, and application of Lockdown, are expected to significantly reduce the incidence of influenza. Vaccination In the southern hemisphere already in Australia, Chile and South Africa there have been reduced cases of influenza. However, in areas such as Southeast Asia, where prevention measures are limited, there are outbreaks of the flu virus. Although the effectiveness of the flu vaccine may vary from year to year and age group, the value of vaccinating the population is unquestionable, as it has been estimated that vaccination against influenza virus prevented the period 2010-2020. 1.4 to 7.5 million infections, 0.7 to 3.5 million doctor visits, 39,000 to 105,000 hospitalizations and 3,500 to 12,000 deaths in the US per year. Who has an increased risk of developing complications from the fluMany population groups have an increased risk of developing complications from the flu. These groups include young children under 5 years (especially under 2 years), pregnant and pregnant women, the elderly over 65 years, people with chronic health problems (such as asthma, COPD, pulmonary fibrosis, neurological diseases, hematological disorders, chronic kidney disease or liver disease, metabolic diseases, obesity, etc.), those living in nursing homes, and racial minorities. The best way to prevent the flu virus is the annual vaccination, especially those who have an increased risk of complications. The vaccine is safe for ages over 6 months. There are many different vaccines available for different population groups, and although vaccination is recommended in late October, non-vaccinated people are encouraged to get the vaccine in November or December, in case there are many flu cases. What to do In case of respiratory symptoms In cases of respiratory symptoms, where both infections are possible, a special diagnostic test should be performed to obtain the appropriate treatment options. Even in the absence of fever, groups at increased risk of complications should contact their GP as soon as symptoms appear. Often, the elderly and patients with an inactive immune system may not develop a fever. The flu can worsen pre-existing comorbidities, such as chronic obstructive pulmonary disease, asthma, heart failure and diabetes. It is worth noting that antiviral therapy can reduce the likelihood of complications, especially if started within 48 hours of the onset of symptoms. Especially in hospitalized or outpatients with a high risk of serious complications, early initiation is very important. antiviral therapy with oseltamivir or zanamivir. In patients treated with COVID-19 infection, there are insufficient data on the efficacy or immunogenicity and safety of influenza vaccines to determine the optimal timing of vaccination. In addition, the optimal vaccination time for those receiving the vaccine has not been determined. anti-inflammatory drugs such as dexamethasone or long-acting immunomodulators. serious infection to be postponed until recovery, but should not be omitted. Follow it on Google News and be the first to know all the news See all the latest news from Greece and the world, at



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *